Diffuse lung disease: A view for the future

Sarcoidosis Vasculitis and Diffuse Lung Disease

Volumn 14, Issue 1, 1997, Pages 23-30

  Du Bois, R M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Bronchoalveolar lavage; Computed tomography; Diffuse lung disease; DTPA; Interstitial lung disease; Lung biopsy

Indexed keywords

PENTETIC ACID;

COMPUTER ASSISTED TOMOGRAPHY; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG LAVAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

BIOPSY; BRONCHOALVEOLAR LAVAGE; HUMANS; LUNG DISEASES, INTERSTITIAL; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0030893183     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Office of Population Censuses and Surveys. Mortality statistics 1979-92. London: HMSO, 1980-93 (Series DH2).
2. Hubbard R, Johnston I, Coultas DB, Britton J: Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax 1996; 51: 711-716.
3. Coultas DB, Hughes MP: Accuracy of mortality data for interstitial lung diseases in New Mexico, USA. Thorax 1996; 51: 717-720.
4. Johnston I, Britton J, Kinnear W, Logan R: Rising mortality from cryptogenic fibrosing alveolitis. Br Med J 1990; 301: 1017-1021.
5. US Department of Health Education and Welfare, Respiratory Diseases Task Force. Report on problems, research, approaches, and needs. DHEW publication no NIH 76-432 Washington DC: US Government Printing Office: 1976.
6. Johnston IDA, Bleasdale C, Hind CRK, Woodchock AA: Accuracy of diagnostic coding of hospital admissions for cryptogenic fibrosing alveolitis. Thorax 1991; 46: 589-591.
7. Baughman RP: Use of bronchoscopy in the diagnosis of infection in the immunocompromized host. Thorax 1994; 49: 3-7.
8. du Bois RM: Bronchoalveolar lavage. In: Pounder RE, Chiodini PL, eds. Advanced Medicine 23. London: Bailliere Tindall, 1987; 21-29.
9. Agostini C, Semenzato G: Does analysis of bronchoalveolar lavage fluid provide a tool to monitor disease progression or to predict survival in patients with HIV-1 infection? Thorax 1994; 49: 848-851.
10. Rosiello RA, Merrill WW, Rockwell S et al: Radiation pneumonitis: bronchoalveolar lavage assessment and modulation by a recombinant cytokine. Am Rev Respir Dis 1993; 148: 1671-1676.
11. Forni A: Bronchoalveolar lavage in the diagnosis of hard metal disease. Science of the Total Environment 1994; 150: 69-76.
12. Coudert B, Bailly F, Lombard JN, Andre F, Camus P: Amiodarone pneumonitis: Bronchoalveolar lavage findings in 15 patients and review of the literature. Chest 1992; 102: 1005-1012.
13. Reynolds HY: Bronchoalvolar lavage. Am Rev Respir Dis 1987; 135: 250-263.
14. Akoun GM, Cadranel JL, Rosenow EC, 3d, Milleron BJ: Bronchoalveolar lavage cell data in drug-induced pneumonitis. Allergie et Immunologie 1991; 23: 245-252.
15. Goldstein RA, Rohatgi PK, Bergofsky EH et al: Clinical role of bronchoalveolar lavage in adults with pulmonary disease [see comments]. Am Rev Respir Dis 1990; 142: 481-486.
16. Casolaro MA, Bernaudin JF, Saltini C, Ferrans VJ, Crystal RG: Accumulation of Langerhans' cells on epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988; 137: 406-111.
17. Hance AJ: Pulmonary immune cells in health and disease: dendritic cells and Langerhans' cells. Eur Respir J 1993; 6: 1213-1220.
18. Tazi A, Bonay M, Grandsaigne M, Battesti J, Hance AJ, Soler P: Surface phenotype of Langerhans cells and lymphocytes in granulomatous lesions from patients with pulmonary histiocytosis X. Am Rev Respir Dis 1993; 147: 1531-1536.
19. Haslam PL, Turton CWG, Lukoszek A et al: Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35: 328-339.
20. Drent M, Mulder PG, Wagenaar SS, Hoogsteden HC, van Velzen-Blad H, van den Bosch JM: Differences in BAL fluid variables in interstitial lung diseases evaluated by discriminant analysis. Eur Respir J 1993; 6: 803-810.
21. BAL cooperative group steering committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990; 141: S169-S202.
22. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group on BAL. Eur Respir J 1989; 2: 561-585.
23. Klech H, Haslam P, Turner-Warwick M: World wide clinical survey on bronchoalveolar lavage (BAL) in sarcoidosis. Experience in 62 centers in 19 countries. Preliminary analysis. Sarcoidosis 1986; 3: 113-122.
24. Wells AU, Hansell DM, Rubens MB et al: Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation 10 computed tomographic appearance. Am J Respir Crit Care Med 1994; 150: 462-468.
25. Semenzato G, Agostini C, Zambello R et al: Activated T cells with immunoregulatory functions at different sites of involvement in sarcoidosis. Phenotypic and functional evaluations. Ann N Y Acad Sci 1986; 465: 56-73.
26. King TE Jr, Mortenson RL: Bronchoalveolar lavage in patients with connective tissue disease. J Thorac Imag 1992, 7: 26-48.
27. Costabel U: The alveolitis of hypersensitivity pneumonitis. Eur Respir J 1988; 1: 5-9.
28. Wells AU, Hansell DM, Cailes J et al: Bronchoalveolar lavage (BAL) cellularity in fibrosing alveolitis: a comparison between lone cryptogenic fibrosing alveolitis (CFA) and the fibrosing alveolitis of systemic sclerosis (FASSc). Eur Respir J 1995; 8: 453s (Abstract).
29. Weinberger SE, Kelmanm JA, Elson NA et al: Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med 1978; 89: 459-466.
30. Wells AU, Hansell DM, Rubens MB et al: Fibrosing alveolitis in systemic sclerosis: bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 1994, 150: 462-468.
31. Watters LC, Schwarz MI, Cherniack RM: Idiopathic pulmonary fibrosis: pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135: 696-704.
32. Turner-Warwick M, Haslam PL: The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987; 135: 26-34.
33. Schwartz DA, Helmers RA, Galvin JR et al: Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 450-454.
34. Schwartz DA, Van Fossen DS, Davis CS et al: Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 444-449.
35. Drent M, van Nierop AMF, Gerritsen FA, Wouters EFM, Mulder PG: A computer programme using BALF-analysis results as a diagnostic tool in interstitial lung disease. Am J Respir Crit Care Med 1996; 153: 736-741.
36. Remy-Jardin M, Giraud F, Remy J, Wattinne L, Wallaert B, Duhamel A: Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment. Radiology 1994; 191: 675-680.
37. Remy-J M, Remy J, Cortet B, Mauri F, Delcambre B: Chances in Reumatoid arthrites: CJ findings. Radiology 1994, 193: 375-382.
38. Batra P: Role of high-resolution CT in the diagnosis and evaluation of pulmonary sarcoidosis. Sarcoidosis 1993; 10: 95-97.
39. Hartman TE, Primack SL, Swensen SJ, Hansell D, McGuinness G, Muller NL: Desquamative interstitial pneumonia: thin-section CT findings in 22 patients. Radiology 1993; 187: 787-790.
40. Leung AN, Miller RR, Muller NL: Parenchymal opacification in chronic infiltrative lung diseases: CT-pathologic correlation. Radiology 1993; 188: 209-214.
41. Padley SP, Adler B, Muller NL: High-resolution computed tomography of the chest: current indications. J Thorac Imag 1993; 8: 189-199.
42. Primack SL, Hartman TE, Hansell DM, Muller NL: End-stage lung disease: CT findings in 61 patients. Radiology 1993; 189: 681-686.
43. Primack SL, Hartman TE, Ikezoe J, Akira M, Sakatani M, Muller NL: Acute interstitial pneumonia: radiographic and CT findings in nine patients [see comments]. Radiology 1993; 188: 817-820.
44. Remy-Jardin M, Remy J, Giraud F, Wattinne L, Gosselin B: Computed tomography assessment of ground-glass opacity: semiology and significance. J Thorac Imag 1993; 8: 249-264.
45. Remy-Jardin M, Giraud F, Remy J, Copin MC, Gosselin B, Duhamel A: Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993; 189: 693-698.
46. Remy-Jardin M, Remy J, Wallaert B, Muller NL: Subacute and chronic bird breeder hypersensitivity pneumonitis: sequential evaluation with CT and correlation with lung function tests and bronchoalveolar lavage. Radiology 1993; 189: 111-118.
47. Tung KT, Wells AU, Rubens MB, Kirk JME, du Bois RM, Hansell DM: Accuracy of typical computed tomographic appearances of fibrosing alveolitis. Thorax 1993; 48: 334-338.
48. Wells AU, Hansell DM, Rubens MB, Culliman P, Black CM, du Bois RM: The predictive value of appearances on thin section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148: 1076-1082.
49. Wells AU, Rubens MB, du Bois RM, Hansell DM: Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. Am J Roentgenol 1993; 161: 1159-1165.
50. Hansell DM: Computed tomographic diagnosis of diffuse lung disease. Curr Opin Radiol 1992; 4: 69-78.
51. Remy-Jardin M, Remy J, Deffontaines C, Duhamel A: Assessment of diffuse infiltrative lung disease: comparison of conventional CT and high-resolution CT. Radiology 1991; 181: 157-162.
52. Bergin CJ, Bell DO, Coblentz CL et al: Sarcodosis: correlation of pulmonary parenchymal pattern at CT with results of pulmonary function tests. Radiology 1989; 171: 619-624.
53. Muller NL, Miller RR: Computed tomography of chronic diffuse infiltrative lung disease. Part 1. Am Rev Respir Dis 1990; 142: 1206-1215.
54. Muller NL, Miller RR: Computed tomography of chronic diffuse infiltrative lung disease. Part 2. Am Rev Respir Dis 1990; 142: 1440-1448.
55. Muller NL, Staples CA, Miller RR, Vedal S, Thurlbeck WM, Ostrow DN: Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation. Radioloey 1987; 165: 731-734.
56. Muller NL, Miller RR, Webb WR, Evans KG, Ostrow DN: Fibrosing alveolitis: CT-pathologic correlation. Radiology 1986; 160: 585-588.
57. Muller NL: Clinical value of high resolution CT in chronic diffuse lung disease. Am J Roentgenol 1991; 157: 1163-1170.
58. Mathieson JR, Mayo JR, Staples CA, Muller NL: Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radioeraphy. Radiology 1989; 171: 111-116.
59. Muller NL, Kullnig P, Miller RR: The CT findings of pulmonary sarcoidosis: analysis of 25 patients. Am J Roentgenol 1989; 152: 1179-1182.
60. Muller NL, Mawson JB, Mathieson JR, Abboud R, Ostrow DN, Champion P: Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology 1989; 171: 613-618.
61. Nishimura K, Izumi T, Kitaichi M, Nagai S, Itoh H: The diagnostic accuracy of high resolution computed tomography in diffuse infiltrative lung diseases. Chest 1993; 104: 1149-1155.
62. Al Jarad N, Gellert AR, Rudd RM: Bronchoalveolar lavage and 99mTc-DTPA clearance as prognostic factors in asbestos workers with and without asbestosis. Respir Med 1993; 87: 365-374.
63. Bourke SJ, Banham SW, McKillop JH, Boyd G: Clearance of 99mTc-DTPA in pigeon fancier's hypersensitivity pneumonitis. Am Rev Respir Dis 1990; 142: 1168-1171.
64. Chinet T, Dusser D, Labrune S, Collignon MA, Chrétien J, Huchon GJ: Lung function declines in patients with pulmonary sarcoidosis and increased respiratory epithelial permeability to 99mTc-DTPA. Am Rev Respir Dis 1990; 141: 445-449.
65. Dusser DJ, Collignon MA, Stanislas-Leguern G, Barritault LG, Chrétien J, Huchon GJ: Respiratory clearance of 99mTc-DTPA and pulmonary involvement in sarcoidosis. Am Rev Respir Dis 1986; 134: 493-197.
66. Fanti S, De Fabritiis A, Aloisi D et al: Early pulmonary involvement in systemic sclerosis assessed by technetium-99m-DTPA clearance rate. J Nucl Med 1994; 35: 1933-1936.
67. Kao CH, Lin HT, Yu SL, Wang SJ, Yeh SH: Relationship of alveolar permeability and lung inflammation in patients with active diffuse infiltrative lung disease detected by 99Tcm-DTPA radioaerosol inhalation lung scintigraphy and quantitative Ga lung scans. Nucl Med Comm 1994; 15: 850-854.
68. Labrune S, Chinet T, Collignon MA, Barritault L, Huchon GJ: Mechanisms of increased epithelial lung clearance of DTPA in diffuse fibrosing alveolitis. Eur Respir J 1994; 7: 651-656.
69. Line BR: Scintigraphic studies of inflammation in diffuse lung disease. Radiol Clin North Am 1991; 29: 1095-1114.
70. Nery LE, Florencio RT, Sandoval PR, Rodrigues RT, Alonso G, Mason GR: Additive effects of exposure to silica dust and smoking on pulmonary epithelial permeability: a radioaerosol study with technetium-99m labelled DTPA. Thorax 1993; 48: 264-268.
71. Rosso J, Guillon JM, Parrot A et al: Technetium-99m-DTPA aerosol and gallium-67 scanning in pulmonary complications of human immunodeficiency virus infection. J Nucl Med 1992; 33: 81-87.
72. Suga K, Ariyoshi I, Nishigauchi K et al: Altered regional clearance of 99Tcm-DTPA in radiation pneumonitis. Nucl Med Comm 1992; 13: 357-364.
73. Susskind H, Rom WN: Lung inflammation in coal miners assessed by uptake of 67Ga-citrate and clearance of inhaled 99mTc-labeled diethylenetriamine pentaacetate aerosol. Am Rev Respir Dis 1992; 146: 47-52.
74. Susskind H, Weber DA, Volkow ND, Hitzemann R: Increased lung permeability following long-term use of free-base cocaine (crack). Chest 1991; 100: 903-909.
75. Taleno M, Nakano A, Hasegawa A et al: [Pulmonary clearance of 99mTc-DTPA aerosol in patients with progressive systemic scheloderma]. [Japanese]. Kaku Igaku - Jap J Nucl Med 1992; 29: 585-590.
76. Thunberg S, Larsson K, Eklund A, Blaschke E: 99mTc-DTPA clearance measured by a dual head gamma camera in healthy subjects and patients with sarcoidosis. Studies of reproducibility and relation to bronchoalveolar lavage findings. European Journal of Nuclear Medicine 1989; 15: 71-77.
77. Ugur O, Caner B, Balbay MD et al: Bleomycin lung toxicity detected by technetium-99m diethylene triamine penta-acetic acid aerosol scintigraphy. Eur J Nucl Med 1993; 20: 114-118.
78. Uh S, Lee SM, Kim HT, Chung Y, Kim YH, Park CS: The clearance rate of alveolar epithelium using 99mTc-DTPA in patients with diffuse infiltrative lung diseases. Chest 1994; 106: 161-165.
79. Wells AU, Hansell DM, Harrison NK, Lawrence R, Black CM, du Bois RM: Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis [see comments]. Eur Respir J 1993; 6: 797-802.
80. Yeh SH, Liu RS, Wu LC, Peng NJ, Lu JY: 99Tcm-HMPAO and 99Tcm-DTPA radioaerosol clearance measurements in idiopathic pulmonary fibrosis. Nucl Med Comm 1995; 16: 140-144.
81. Schmekel B, Wollmer P, Venge P, Linden M, Blom-Bulow B: Transfer of 99mTc-DTPA and bronchoalveolar lavage findings in patients with asymptomatic extrinsic allergic alveolitis. Thorax 1990; 45: 525-529.
82. Harrison K, Glanville AR, Corrin B, Lawrence R, Woodcock A, Turner-Warwick M: Rapid 99m-Tc DTPA clearance from the lungs in idiopathic pulmonary haemosiderosis (IPH). Am Rev Respir Dis 1989; 139: A472 (Abstract).
83. Harrison NK, Glanville AR, Strickland B et al:: Pulmonary involvement in systemic sclerosis: the detectin of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med 1989; 83: 403-414.
84. Nakano A, Yamaguchi E, Naitoh S et al: Assessment of alveolar epithelial permeability in progressive systemic sclerosis(PSS) using 99mTc-DTPA (diethylene triamine penta acetate) aerosol inahaltion. [Japanese]. Nippon Kyobu Shikkan Gakkai Zasshi - Jap J Thorac Dis 1992; 30: 45-50.
85. Wells AU, Hansell DM, Harrison NK, Lawrence R, Black CM, du Bois RM: Clearance of inhaled 99m-Tc DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J 1993; 6: 797-802.
86. Barrowcliffe MP, Jones LG: Solute permeability of the alveolar capillary barrier. Thorax 1987; 42: 1-10.
87. Jones JG, Minty BD, Lawler P, Hulands G, Crowley JCW, Veall N: Increased alveolar permeability in cigarette smokers. Lancet 1980; i: 66-68.
88. Mason GR, Uszler JM, Effros RM, Reid E: Rapidly reversible alterations of pulmonary epithelial permeability induced by smoking. Chest 1983; 83: 6-11.
89. Jones JG, Minty BD, Royston D: The physiology of leaky lungs. Br J Anaes 1982; 54: 705-721.
90. Mordelet-Dambrine M, Leguern-Stanislas G, Chinet TC, Barritault L, Chrétien J, Huchon GJ: Effects of tobacco smoke on respiratory epithelial clearance of DTPA and on lung histology in rats. Eur Respir J 1991; 4: 839-844.
91. Mitchell DM, Emerson CJ, Collins JV, Stableforth DE: Transbronchial lung biopsy with the fiberoptic bronchoscope. Analysis of results in 433 patients. Br J Dis Chest 1981; 75: 258-262.
92. Gilman MJ, Wang KP: Transbronchial lung biopsy in sarcoidosis. Am Rev Respir Dis 1980; 122: 721-724.
93. Shah SS, Tsang V, Goldstraw P: Open lung biopsy: a safe, reliable and accurate method for diagnosis in diffuse lung disease. Respiration 1992; 59: 243-246.
94. Venn GE, Kay PH, Midwood CJ, Goldstraw PJ: Open biopsy in patients with diffuse pulmonary shadowing. Thorax 1985; 40: 931-935.
95. Krasna MJ, White CS, Aisner SC, Templeton PA, McLaughlin JS: The role of thoracoscopy in the diagnosis of interstitial lung disease. Ann Thorac Surg 1995; 59: 348-351.
96. Nasim A, Akhtar RP, Spyt TJ: Video-thoracoscopic lung biopsy in diagnosis of interstitial lung disease. J R Coll Surg Edin 1995; 40: 22-24.
97. Carnochan FM, Walker WS, Cameron EWJ: Efficacy of video assisted thoracoscopic lung biopsy: an historical comparison with open lung biopsy. Thorax 1994; 49: 361-363.
98. Molin LJ, Steinberg JB, Lanza LA: VATS increases costs in patients undergoing lung biopsy for interstitial lung disease. Ann Thorac Surg 1994; 58: 1595-1598.
99. Bensard DD, McIntyre RC Jr, Waring BJ, Simon JS: Comparison of video thoracoscopic lung biopsy to open lung biopsy in the diagnosis of interstitial lung disease. Chest 1993; 103: 765-770.
100. Wells AU, Cullinan P, Hansell DM et al: Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149: 1583-1590.
101. Wells AU, Hansell DM, Rubens MB, Cailes JB, Black CM, du Bois RM: Functional impairment in lone cryptogenic fibrosing alveolitis with systemic sclerosis: a comparison. Am J Respir Crit Care Med 1997 In Press.
102. Agusti C, Xaubert A, Roca J et al: Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up. Thorax 1992; 47: 1035-1040.
103. Roschman RA: Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy. Semin Arthritis Rheumatol 1987; 16: 174-185.
104. Schwartz MI, Matthay RA, Sahn SA et al: Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine 1976; 55: 89-104.
105. Wallaert B, Perez T, Tonnel A: The lung in rheumatological diseases. In: Walters EH, du Bois RM, eds. Immunology and Management of Interstitial Lung Diseases. Oxford: Chapman & Hall, 1995; 235-253.
106. Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, du Bois RM: The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148: 1076-1082.
107. Turner-Warwick M, Burrows B, Johnson A: Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and ils effect on survival. Thorax 1980; 35: 593-599.
108. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M: Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-288.
109. Tukiainen P, Taskinen E, Holsti P, Korhola P, Valle M: Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38: 349-355.
110. Raghu G, DePaso WJ, Cain K et al: Azathioprine combined with prednisolone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296.
111. Hoffman GS, Kerr GS, Leavitt RY et al: Wegener's granulomatosis: an analysis of 158 patients. Am Intern Med 1992; 116: 488-498.
112. Hoffman GS, Leavitt RY, Fleischer TA et al: Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403-410.
113. Jayne DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337: 1137-1139.
114. Harrison NK, Wells AU, Hansell DM, Black CM, du Bois RM: Treatment of lung disease in systemic sclerosis: a clinical comparison of responders and non-responders. Am Rev Respir Dis 1992; 145: A755 (Abstract).
115. Zaki MH, Lyons HA, Leilop L, Huang CT: Corticosteroid therapy in sarcoidosis. A five year, controlled follow-up study. NY State J Med 1987; 87: 496-199.
116. Israel HL: Corticosteroid treatment of sarcoidosis - who needs it? NY State J Med 1987; 87: 490.
117. Selroos O, Sellergren T-L: Corticosteroid therapy of pulmonary sarcoidosis: a prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Resp Dis 1979; 60: 215-221.
118. Selroos OB: Use of budesonide in the treatment of pulmonary sarcoidosis. Ann NY Acad Sci 1986; 465: 713-721.
119. British Tuberculosis Association Research Committee. Chloroquine in the treatment of sarcoidosis. Tubercle 1967; 48: 257-272.
120. Hunninghake GW, Gilbert S, Pueringer R et al: Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149: 893-898.
121. Baughman RP, Lower EE, Lynch JP: Treatment modalities for sarcoidosis. Clin Pul Med 1994; 1: 223-231.
122. Gibson GJ, Prescott RJ, Muers M et al: British Thoracic Society Sarcoidosis study: effects of longterm corticosteroid treatment. Thorax 1996; 51: 238-247.
123. Alberts C, van der Mark ThW, Jansen HM et al: Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Eur Respir J 1995; 8: 682-688.
124. McCarty KS, Mossier JA, McLelland R, Sieker HO: Pulmonary lymphangiomyomatosis responsive to progesterone. N Engl J Med 1980; 303: 1461-1465.
125. Eliasson AH, Phillips YY, Tenholder MF: Treatment of lymphangioleiomyomatosis: a meta-analysis. Chest 1989; 196: 1352-1355.